Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Keymed Biosciences, Inc. ( (HK:2162) ) has shared an update.
Keymed Biosciences has provided further details on the planned disposal of its minority equity interest in Ouro Medicines, confirming that closing of the merger remains subject to customary regulatory clearances and must occur before a long stop date that can be extended into 2027. The company expects to recognize an estimated pre-tax gain of about US$240 million from the upfront consideration of approximately US$250 million, with total potential pre-tax gains rising to roughly US$310 million if contingent milestone payments of up to US$70 million are fully achieved.
The board deemed the consideration fair and reasonable, citing the substantial premium over the current carrying value of the stake and the arm’s length nature of negotiations with a large, independently listed global pharmaceutical buyer. Management plans to use around 30% of the proceeds over three years to accelerate commercialization of core products and allocate the remaining 70% to R&D for key pipeline programs, which should bolster cash reserves and support the company’s medium-term development and commercialization strategy.
The most recent analyst rating on (HK:2162) stock is a Buy with a HK$92.67 price target. To see the full list of analyst forecasts on Keymed Biosciences, Inc. stock, see the HK:2162 Stock Forecast page.
More about Keymed Biosciences, Inc.
Keymed Biosciences Inc., incorporated in the Cayman Islands and listed in Hong Kong, operates in the biopharmaceutical industry with a focus on developing and commercializing innovative drug candidates. The company’s core portfolio centers on monoclonal antibodies and other biologics, targeting indications supported by pipeline assets such as CM512, CM518D1, CM313 and CM336 for future growth.
Average Trading Volume: 1,988,504
Technical Sentiment Signal: Buy
Current Market Cap: HK$20.86B
Find detailed analytics on 2162 stock on TipRanks’ Stock Analysis page.